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 In most European countries total healthcare expenditure as % of GDP is stable around the 9 to 11% range since 2008, and pharmaceutical expenditure has been stable around 2% of GDP  Concerns about unaff ordable pricing of some innovative treatments have drawn signifi cant attention; however, assessment procedures scrutinize their added value and are deployed to adjust pricing and restrict coverage to narrow indications and small patient numbers  The upward budget impact of value-priced innovative treatments is compensated by the growing market share of competition-based or cost-plus priced generics and OTC drugs 
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Background:
 Pharmaceutical expenditure as % of GDP has been stable or slightly declining in most European countries in the last 10 years, in spite of concerns about skyrocketing pharmaceutical prices  The fl attening of the growth curve of pharmaceutical expenditure is concomitant with the "patent cliff ": the going off -patent of many blockbuster drugs  The pharmaceutical market in Europe shows three kinds of approaches to pricing strategies: value-based pricing, competitor-based pricing and cost-plus pricing  Through value-based pricing a fair price refl ects therapeutic value, economic value and maybe societal value. In competitor-based pricing a fair price mimics the price of direct competitors. Cost-plus pricing sets the price by adding a fair margin to the cost of manufacturing and handling Objectives:
 Describe the segmentation of the European pharmaceutical market by applicable pricing strategy: 1) Innovative patent protected products, priced by clinical and economic value 2) Medicines with interchangeable alternatives (generics, hybrids, biosimilars), competitor-based priced 3) Low-priced small-molecule generics and OTCs, cost-plus priced with narrow margins  Understand the nature of the contribution of value-based pricing to the sustainability of pharmaceutical expenditure in Europe  Demonstrate that value-based pricing, in combination with the other pricing strategies in their respective market segments, will enable developed healthcare systems to contain growth of total pharmaceutical expenditure at a sustainable level Methods:
 Analyze value/HTA assessment and cost-containment policies in European markets  Review healthcare and pharmaceutical expenditure in Europe, and the distribution thereof between patent protected medicines, generics, and OTC drugs  Use the Simon-Kucher project experience with pricing strategies of innovative products, mature products, generics/biosimilars, and OTC medications, as well as commercial pricing and contracting strategies (e.g. commercial discounting and tendering)
Results: Pharmaceutical innovation with sustainability 1. Over the last decade practically all European markets moved towards more or less formalized value/HTA assessment of products submitted for reimbursement, setting allowable launch price by a combination of therapeutic value, economic value, budget impact and international price referencing 2. Products with signifi cant added therapeutic value continue to achieve premium prices, though the required added clinical benefi t for a price premium is increasing, and often the covered patient sub-population is restricted 3. Simultaneously, the majority of EU countries adopted rules for fi xed reference pricing, clustering products after patent expiry with respective generics at market entry, invariably leading to a steep decline in the cost of treatment 4. At the lowest price segment of the market, an increasing number of small-molecule generics and OTCs is sourced at very low price, often from low-income countries 5. Regional authorities, sick funds, budget holders, hospitals and other sub-national payers further negotiate discounts and drive generic substitution, showing commercial behaviors similar to fast-moving-goods 6. The checks and balances in this fi nely woven fabric of pricing dynamics in the pharmaceutical market generate a pattern of sustainable growth in which therapeutic innovation with added clinical value continues to fi nd its place 
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